Rayner launches spiral IOL designed by AI

News
Article

The RayOne Galaxy and Galaxy Toric IOL will launch at this year's ESCRS Congress in Barcelona, Spain.

Two boxes of of Rayner IOLs Image credit: Rayner

Image credit: Rayner

On Monday, ophthalmic surgery manufacturer Rayner announced a new addition to its intraocular lens (IOL) offering, designed using a proprietary artificial intelligence (AI) engine. In a press release, Rayner, based in Worthing, UK, shared details about the RayOne Galaxy and Galaxy Toric, which will launch at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) Congress in Barcelona, Spain.1 The lens will come fully preloaded across the RayOne product line’s power range and will be immediately available in toric powers.

According to Rayner, the RayOne Galaxy has a unique spiral lens, formulated to deliver a continuous full range of vision and minimise dysphotopsia. The company developed the RayOne Galaxy in conjunction with João Marcelo Lyra, MD, PHD, who is affiliated with Universidade Estadual de Ciências da Saúde de Alagoas (UNCISAL), Maceio, Alagoas, Brazil. Additionally, the IOL was developed using an AI “trained on patient outcomes,” resulting in a non-diffractive optic with 0% light loss. The press release from Rayner noted the lens is the “world’s first spiral IOL designed with artificial intelligence.”

Clinical investigations with RayOne Galaxy began earlier in 2024 in Brazil and throughout Europe.1 Eight leading surgeons began using the RayOne Galaxy in their clinical practices, and a number of those surgeons will present initial findings at a Rayner symposium during the ESCRS Congress. Mr Allon Barsam, Consultant Ophthalmic Surgeon and Director at OCL Vision in London, United Kingdom, said the first patients received the RayOne Galaxy lens at OCL Vision in July. “Their feedback so far has been overwhelmingly positive, with patients reading without glasses and thrilled with their quality of vision,” Mr Barsam reported in the press release.

Tim Clover, CEO of Rayner, gave a statement about the AI-supported development of the lens. “We all read about the life changing potential of AI, but this is a real-world example of technology impacting the outcomes of patients,” he said. “RayOne Galaxy represents a next generation technology in intraocular lenses to enable patients to see without spectacles.”

Reference:
  1. Rayner announces launch of world’s first spiral IOL designed with AI. Press release. Rayner Group. Published 26 August, 2024.
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.